Stock Analysis
- Hong Kong
- /
- Food and Staples Retail
- /
- SEHK:6618
A Look At The Fair Value Of JD Health International Inc. (HKG:6618)
Key Insights
- JD Health International's estimated fair value is HK$23.95 based on 2 Stage Free Cash Flow to Equity
- With HK$23.40 share price, JD Health International appears to be trading close to its estimated fair value
- Analyst price target for 6618 is CN¥33.23, which is 39% above our fair value estimate
In this article we are going to estimate the intrinsic value of JD Health International Inc. (HKG:6618) by taking the expected future cash flows and discounting them to today's value. One way to achieve this is by employing the Discounted Cash Flow (DCF) model. It may sound complicated, but actually it is quite simple!
Remember though, that there are many ways to estimate a company's value, and a DCF is just one method. If you still have some burning questions about this type of valuation, take a look at the Simply Wall St analysis model.
See our latest analysis for JD Health International
Crunching The Numbers
We are going to use a two-stage DCF model, which, as the name states, takes into account two stages of growth. The first stage is generally a higher growth period which levels off heading towards the terminal value, captured in the second 'steady growth' period. In the first stage we need to estimate the cash flows to the business over the next ten years. Where possible we use analyst estimates, but when these aren't available we extrapolate the previous free cash flow (FCF) from the last estimate or reported value. We assume companies with shrinking free cash flow will slow their rate of shrinkage, and that companies with growing free cash flow will see their growth rate slow, over this period. We do this to reflect that growth tends to slow more in the early years than it does in later years.
Generally we assume that a dollar today is more valuable than a dollar in the future, and so the sum of these future cash flows is then discounted to today's value:
10-year free cash flow (FCF) estimate
2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 | |
Levered FCF (CN¥, Millions) | CN¥6.24b | CN¥7.54b | CN¥3.33b | CN¥4.01b | CN¥3.46b | CN¥3.15b | CN¥2.97b | CN¥2.87b | CN¥2.83b | CN¥2.81b |
Growth Rate Estimate Source | Analyst x7 | Analyst x6 | Analyst x1 | Analyst x1 | Est @ -13.78% | Est @ -8.97% | Est @ -5.61% | Est @ -3.25% | Est @ -1.60% | Est @ -0.44% |
Present Value (CN¥, Millions) Discounted @ 6.2% | CN¥5.9k | CN¥6.7k | CN¥2.8k | CN¥3.1k | CN¥2.6k | CN¥2.2k | CN¥1.9k | CN¥1.8k | CN¥1.6k | CN¥1.5k |
("Est" = FCF growth rate estimated by Simply Wall St)
Present Value of 10-year Cash Flow (PVCF) = CN¥30b
The second stage is also known as Terminal Value, this is the business's cash flow after the first stage. The Gordon Growth formula is used to calculate Terminal Value at a future annual growth rate equal to the 5-year average of the 10-year government bond yield of 2.3%. We discount the terminal cash flows to today's value at a cost of equity of 6.2%.
Terminal Value (TV)= FCF2034 × (1 + g) ÷ (r – g) = CN¥2.8b× (1 + 2.3%) ÷ (6.2%– 2.3%) = CN¥72b
Present Value of Terminal Value (PVTV)= TV / (1 + r)10= CN¥72b÷ ( 1 + 6.2%)10= CN¥39b
The total value, or equity value, is then the sum of the present value of the future cash flows, which in this case is CN¥70b. The last step is to then divide the equity value by the number of shares outstanding. Compared to the current share price of HK$23.4, the company appears about fair value at a 2.3% discount to where the stock price trades currently. Remember though, that this is just an approximate valuation, and like any complex formula - garbage in, garbage out.
Important Assumptions
We would point out that the most important inputs to a discounted cash flow are the discount rate and of course the actual cash flows. You don't have to agree with these inputs, I recommend redoing the calculations yourself and playing with them. The DCF also does not consider the possible cyclicality of an industry, or a company's future capital requirements, so it does not give a full picture of a company's potential performance. Given that we are looking at JD Health International as potential shareholders, the cost of equity is used as the discount rate, rather than the cost of capital (or weighted average cost of capital, WACC) which accounts for debt. In this calculation we've used 6.2%, which is based on a levered beta of 0.800. Beta is a measure of a stock's volatility, compared to the market as a whole. We get our beta from the industry average beta of globally comparable companies, with an imposed limit between 0.8 and 2.0, which is a reasonable range for a stable business.
SWOT Analysis for JD Health International
- Earnings growth over the past year exceeded the industry.
- Currently debt free.
- Earnings growth over the past year is below its 5-year average.
- Annual earnings are forecast to grow faster than the Hong Kong market.
- Current share price is below our estimate of fair value.
- Revenue is forecast to grow slower than 20% per year.
Looking Ahead:
Although the valuation of a company is important, it ideally won't be the sole piece of analysis you scrutinize for a company. The DCF model is not a perfect stock valuation tool. Rather it should be seen as a guide to "what assumptions need to be true for this stock to be under/overvalued?" If a company grows at a different rate, or if its cost of equity or risk free rate changes sharply, the output can look very different. For JD Health International, we've put together three essential elements you should consider:
- Financial Health: Does 6618 have a healthy balance sheet? Take a look at our free balance sheet analysis with six simple checks on key factors like leverage and risk.
- Management:Have insiders been ramping up their shares to take advantage of the market's sentiment for 6618's future outlook? Check out our management and board analysis with insights on CEO compensation and governance factors.
- Other Solid Businesses: Low debt, high returns on equity and good past performance are fundamental to a strong business. Why not explore our interactive list of stocks with solid business fundamentals to see if there are other companies you may not have considered!
PS. The Simply Wall St app conducts a discounted cash flow valuation for every stock on the SEHK every day. If you want to find the calculation for other stocks just search here.
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About SEHK:6618
JD Health International
An investment holding company, engages in the operation of an online healthcare platform in the People’s Republic of China and internationally.